阿克拉霉素治疗老年急性非淋巴细胞白血病患者

Aclarubicin in the treatment of elderly patients with acute nonlymphocytic leukemia.

作者信息

Takahashi I, Yorimitsu S, Hara M, Inagaki T, Nakada H, Sekito N, Hayashi N, Nonaka K, Ohmoto E, Uchida K

出版信息

Acta Med Okayama. 1986 Jun;40(3):175-7. doi: 10.18926/AMO/31932.

DOI:10.18926/AMO/31932

Abstract

Thirteen previously untreated patients aged 70 and above with acute nonlymphocytic leukemia were treated with aclarubicin (ACR) alone. Among 10 cases (3, acute myelocytic leukemia; 4, acute myelomonocytic leukemia; 2, acute monocytic leukemia; and one, acute erythroleukemia) in which an evaluation was possible, 5 cases (3, acute myelomonocytic leukemia; and 2, acute monocytic leukemia) obtained complete remission (CR). The CR rate was 83% in 6 patients with acute myelomonocytic leukemia or acute monocytic leukemia. The median CR duration and survival was 7.5 and 10 + months, respectively. Although side effects of the drug on digestive system such as nausea, vomiting and anorexia were observed in all patients, they were controllable by conventional treatments. The results suggest that ACR is effective for the clinical management of elderly patients with acute nonlymphocytic leukemia, especially those with acute myelomonocytic leukemia or acute monocytic leukemia.

摘要

13名年龄在70岁及以上的初治急性非淋巴细胞白血病患者接受了单独的阿克拉霉素（ACR）治疗。在10例可评估的患者中（3例急性髓细胞白血病；4例急性粒单核细胞白血病；2例急性单核细胞白血病；1例急性红白血病），5例（3例急性粒单核细胞白血病；2例急性单核细胞白血病）获得完全缓解（CR）。6例急性粒单核细胞白血病或急性单核细胞白血病患者的CR率为83%。CR持续时间和生存期的中位数分别为7.5个月和10多个月。虽然所有患者均观察到该药物对消化系统的副作用，如恶心、呕吐和厌食，但通过常规治疗这些副作用是可控的。结果表明，ACR对老年急性非淋巴细胞白血病患者，尤其是急性粒单核细胞白血病或急性单核细胞白血病患者的临床治疗有效。